Ondansetron | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Ondansetron
HEALTH CANADA PATENTS

PharmaCompass Sponsored Ads

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Contact Supplier

Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Ondansetron

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

23 API Suppliers, 8 USDMF, 8 EU WC, 3 KDMF, 7 NDC API, 19 Listed Suppliers, $ API Reference Price

23 API Suppliers
8 USDMF
8 EU WC
3 KDMF
7 NDC API
19 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

35 Drugs in Development

35 Drugs in Development

INTERMEDIATES

10 Intermediates Suppliers

10 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

426 FDF Dossiers, 29 FDA Orange Book, 143 Europe, 26 Canada, 88 Australia, 45 South Africa, 95 Listed Dossiers

426 FDF Dossiers
29 FDA Orange Book
143 Europe
26 Canada
88 Australia
45 South Africa
95 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, ORALLY DISINTEGRATING;ORAL - 4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - 8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM;ORAL - 4MG, FILM;ORAL - 8MG

TABLET, ORALLY DISINTEGRATING;ORAL - 4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, ORALLY DISINTEGRATING;ORAL - 8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
FILM;ORAL - 4MG
FILM;ORAL - 8MG

RELATED EXCIPIENT COMPANIES

1 Minakem, 6 Rochem International Inc, 22 SPI Pharma, 2 Seqens, 10 DKSH, 3 Jai Radhe Sales, 2 Pharm-RX Chemical, 6 Faran Shimi Pharmaceutical, 4 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 16 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 ACG Worldwide, 9 Actylis, 2 Aeon Procare, 2 Alcedo Pharmachem, 10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 17 BASF, 1 Bioplus Life Sciences, 11 Corel Pharma Chem, 7 DFE Pharma, 1 Doshion Polyscience, 1 Finar, 11 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 37 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 16 Microlex e.U, 1 Nanjing Bold Chemical, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 2 Novo Excipients, 4 Pharmatrans-Sanaq, 6 Pluviaendo, 5 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 29 Roquette, 13 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 5 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

91 Fillers, Diluents & Binders, 50 Direct Compression, 47 Coating Systems & Additives, 45 Disintegrants & Superdisintegrants, 32 Thickeners and Stabilizers, 27 Controlled & Modified Release, 26 Taste Masking, 25 Granulation, 24 Lubricants & Glidants, 23 Chewable & Orodispersible Aids, 20 Co-Processed Excipients, 19 Solubilizers, 18 Film Formers & Plasticizers, 16 Parenteral, 12 Topical, 9 Empty Capsules, 8 API Stability Enhancers, 7 Emulsifying Agents, 6 Rheology Modifiers, 4 Vegetarian Capsules, 4 Coloring Agents, 2 Surfactant & Foaming Agents, 1 Soft Gelatin

91 Fillers, Diluents & Binders
50 Direct Compression
47 Coating Systems & Additives
45 Disintegrants & Superdisintegrants
32 Thickeners and Stabilizers
27 Controlled & Modified Release
26 Taste Masking
25 Granulation
24 Lubricants & Glidants
23 Chewable & Orodispersible Aids
20 Co-Processed Excipients
19 Solubilizers
18 Film Formers & Plasticizers
16 Parenteral
12 Topical
9 Empty Capsules
8 API Stability Enhancers
7 Emulsifying Agents
6 Rheology Modifiers
4 Vegetarian Capsules
4 Coloring Agents
2 Surfactant & Foaming Agents
1 Soft Gelatin

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 30 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
30 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

130 Finished Drug Prices

130 Finished Drug Prices

MARKET PLACE

14 APIs, 23 FDF Dossiers

14 APIs
23 FDF Dossiers

PATENTS & EXCLUSIVITIES

4 US Patents, 2 Health Canada Patents

4 US Patents
2 Health Canada Patents

REF. STANDARDS & IMPURITIES

4 USP, 9 Others

4 USP
9 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 1,419 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

2 All

01 2GlaxoSmithKline Inc.

filter Patent Reset all filters

2 All

01 22205600

filter Product Reset all filters

2 All

01 2Ondansetron

filter Dosage Reset all filters

2 All

01 2Orally Disintegrating Tablet

filter Exp Date Reset all filters

2 All

01 22015-11-20

Athena Ondansetron

Product Main Page

01

GlaxoSmithKline Inc.

Ondansetron

BioFlorida Conference

Not Confirmed

GlaxoSmithKline Inc.

BioFlorida Conference

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-11-20

Date Granted : 2000-05-30

Ondansetron

Brand Name : ZOFRAN ODT

Patent Number : 2205600

Filing Date : 1995-11-20

Strength per Unit : 4mg

Dosage Form : Orally Disintegrating Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-11-20

Date Granted : 2000-05-30

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

GlaxoSmithKline Inc.

Ondansetron

BioFlorida Conference

Not Confirmed

GlaxoSmithKline Inc.

BioFlorida Conference

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-11-20

Date Granted : 2000-05-30

Ondansetron

Brand Name : ZOFRAN ODT

Patent Number : 2205600

Filing Date : 1995-11-20

Strength per Unit : 8mg

Dosage Form : Orally Disintegrating Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-11-20

Date Granted : 2000-05-30

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?